Temasek leads $80 mln round for Tessa Therapeutics
Singapore-based Tessa Therapeutics, a biopharmaceutical company focusing on T cell therapy for solid tumors, has closed $80 million in financing. Temasek led the round with participation from other investors that included EDBI, Karst Peak Capital, Heliconia and Heritas.
21 December 2017•1 min read
